Two AI-guided surgical clearances arrived in one week, and both automate guidance that once lived entirely in a surgeon's hands. Medtronic's Stealth AXiS cleared for cranial and ENT procedures, the first unified navigation platform to bring AI-based brain mapping and sinus anatomy visualization under one cleared system. On the same day Philips and Edwards announced FDA clearance for DeviceGuide, an AI software that auto-tracks the PASCAL Ace mitral repair device in real time during minimally invasive heart procedures. Neither of these is AI in the background. Both are AI in the OR, live, during the case. On the deal side, Abbott's $21 billion acquisition of Exact Sciences closed, putting the industry's largest liquid biopsy platform inside the world's largest point-of-care diagnostics company. And Samsung quietly consolidated two U.S. imaging subsidiaries into a single brand. It was a week where architecture decisions, in software and in corporate structure, defined the story. Welcome to Issue #9 of The MedTech Minute.
Top Stories
Story 01
Twenty-five years of surgical navigation leadership just got an AI upgrade. The pattern in surgical navigation has been consistent for two decades: add imaging modalities, add anatomical precision, then add intelligence. (Source: PRNewswire, March 27, 2026; Becker's Spine Review)
Medtronic received FDA 510(k) clearance for the Stealth AXiS™ surgical system for both cranial and ear, nose, and throat (ENT) procedures. The clearance expands an existing platform, building on Medtronic's 25-year navigation leadership that began with the LandmarX™ system in 1998.
For cranial procedures, the system includes AI-based automatic tractography, generating patient-specific brain maps and visualizing critical neural pathways. For ENT, it delivers advanced sinus and skull base navigation with sharper anatomical detail and faster responsiveness to support intraoperative decision-making.
The Stealth AXiS is part of Medtronic's AiBLE™ smart surgical ecosystem, integrating planning, navigation, and robotic guidance across procedures. Medtronic's ENT business reaches nearly 3 million patients annually. The single-system clearance covering both cranial and ENT indications expands the commercial footprint of an already-installed infrastructure.
Why This Matters
Automatic tractography is the step that previously required a trained neurophysiologist, or significant manual segmentation time, before a cranial case could proceed. Moving it inside the navigation platform means less pre-op setup, lower center-to-center variability in brain map quality, and a path toward procedure standardization.
For builders working in neuro-navigation or surgical planning software: Medtronic just moved the baseline for what the installed platform can do. Your competitive offering now needs to clear a higher bar to justify a separate system on the same surgical case.
FDA Clearance
AI-Enabled
Neurosurgery
ENT
Story 02
Procedural complexity is the primary barrier to expanding structural heart programs. The interventional cardiologist and the echocardiographer must work in near-constant coordination during mitral transcatheter edge-to-edge repair. That coordination just got an AI assist. (Source: GlobeNewswire, March 26, 2026; MedTech Dive)
Philips received FDA clearance for EchoNavigator R5.0 with DeviceGuide, an AI software solution for mitral transcatheter edge-to-edge repair (M-TEER). Developed with Edwards Lifesciences for the Edwards PASCAL Ace system, DeviceGuide automatically tracks and visualizes the repair device in real time.
It fuses live echocardiography images from the Philips EPIQ CVxi platform with live X-ray from the Philips Azurion image-guided therapy system into a single integrated view. The AI algorithm continuously updates device position without the echocardiographer manually repositioning the imaging window during the case.
M-TEER competes with Abbott's MitraClip in the mitral valve repair market. Early clinical experience with DeviceGuide was published in JACC: Case Reports and the European Heart Journal, providing peer-reviewed backing ahead of commercial rollout. DeviceGuide is intended to support, not replace, the therapeutic procedure itself.
FDA Clearance
AI Software
Structural Heart
Cardiology
Story 03
Corporate rebrands in MedTech are rarely cosmetic. When a company operating two niche subsidiaries consolidates them under the parent's global brand, the usual driver is commercial strategy: unified sales, unified AI platform story, unified competition against integrated imaging leaders. (Source: Imaging Technology News, March 23, 2026)
Samsung Medison announced that its two U.S. medical imaging businesses, previously operating separately as NeuroLogica (portable CT) and Boston Imaging (ultrasound and digital radiography), will unify under a new corporate identity: Samsung HME (Healthcare and Medical Equipment) America. The combined entity covers ultrasound, digital radiography, and CT operations. The rebrand aligns the U.S. businesses with the global Samsung Medison brand and sets the stage for AI product releases and strategic partnerships across imaging modalities in 2026.
NeuroLogica has been a niche leader in portable and point-of-care CT since 2004. Its OmniTom portable head CT is deployed in ICUs, emergency departments, and operating rooms globally. Boston Imaging brings ultrasound distribution strength.
The Samsung HME America umbrella signals ambition to compete as a platform, not just a product portfolio, against GE HealthCare, Siemens Healthineers, and Philips in the U.S. imaging market.
Rebrand
Imaging
AI Strategy
Story 04
Large diagnostics acquisitions take time to reveal their logic. Abbott's $21 billion deal for Exact Sciences was announced in 2025; the close this week marks the moment the integration clock starts. The question was never whether liquid biopsy and multi-cancer early detection would be a large market. The question was who would own the commercial infrastructure when it scaled. (Source: Crain's Chicago Business, March 23, 2026)
Abbott closed its acquisition of Exact Sciences, the Madison, Wisconsin-based molecular diagnostics company behind Cologuard (colorectal cancer screening) and Oncotype DX (breast cancer genomic profiling). Exact Sciences is now a subsidiary of Abbott, adding a leading position in non-invasive cancer screening to Abbott's existing point-of-care, rapid diagnostics, and continuous monitoring portfolios.
Cologuard generated approximately $900 million in revenue in 2024. Abbott's global commercial network and payor relationships create a significant distribution advantage for scaling both Cologuard and the multi-cancer early detection pipeline.
The acquisition positions Abbott to compete directly with Illumina and Guardant Health in the expanding liquid biopsy and early cancer detection market. For hospital systems and oncology practices already using Abbott rapid diagnostics at point of care, Exact Sciences tests on the same Abbott platform would meaningfully reduce friction in the cancer detection pathway.
$21B M&A
Diagnostics
Oncology
Know someone in MedTech who needs this? Forward this issue to a colleague. Five minutes of signal, zero noise.
Market Movers
| Ticker | Company | Price | Wk Change |
|---|
| ISRG | Intuitive Surgical | $488.00 | ▼ 0.2% |
| SYK | Stryker | $394.50 | ▲ 1.1% |
| BDX | BD (Becton Dickinson) | $224.80 | ▼ 0.6% |
| JNJ | Johnson & Johnson | $166.20 | ▲ 1.4% |
| ABT ★ | Abbott | $146.60 | ▲ 2.4% |
| ZBH | Zimmer Biomet | $109.60 | ▼ 1.4% |
| BSX | Boston Scientific | $108.40 | ▲ 0.3% |
| GEHC | GE HealthCare | $93.60 | ▼ 0.6% |
| MDT | Medtronic | $88.20 | ▲ 1.8% |
| EW | Edwards Lifesciences | $77.20 | ▲ 0.6% |
★ Top Mover of the week (biggest % change). Sorted by stock price, highest to lowest. Data shown for illustrative purposes. Prices reflect approximate close, week of March 29, 2026.
Deep Dive
AI in the OR, Why Two Clearances This Week Signal a Structural Shift in Intraoperative Guidance
The operating room has been remarkably resistant to AI. Not because the technology hasn't been there, but because the regulatory bar, the liability structure, and the surgeon workflow dynamics make adoption genuinely difficult. A diagnostic AI can flag a finding and let a radiologist review it. An intraoperative AI has to work in real time, in a patient who is already open, on a schedule that doesn't pause for second opinions.
This week produced two clearances that cleared that bar. Three things are worth unpacking:
- Automatic tractography changes neurosurgical planning economics. Diffusion tensor imaging (DTI)-based tractography, the process of generating patient-specific maps of white matter pathways, has existed for over two decades. What has limited its routine clinical use is the manual time required to segment tracts accurately before a case. Medtronic's AI-based automatic tractography inside Stealth AXiS shortens that workflow. The clinical implication is standardization: less variability in brain map quality between high-volume academic centers and community neurosurgery programs. If tractography quality becomes consistent at scale, the argument for tractography-guided surgery strengthens across a much broader patient population.
- DeviceGuide is a procedural AI, not just an imaging AI. The distinction matters for how you think about where the value accrues. Philips' EchoNavigator with DeviceGuide doesn't analyze a scan and produce a report. It continuously tracks a physical device inside a patient during a live procedure and presents the fused view to the care team without manual realignment. That's closer to a robotic assistance loop than to diagnostic AI. Commercially, it also changes the equipment conversation: hospitals buying the Azurion + EPIQ CVxi combination now get a differentiated M-TEER workflow, not just hardware. Edwards PASCAL Ace procedures become more compatible with those specific Philips platforms, which has downstream implications for competitive positioning in both structural heart interventions and imaging infrastructure procurement.
- The access question is where the real market is. Both clearances this week theoretically enable expansion to centers that previously lacked the expertise to do these procedures at high volume. Community neurosurgery programs that couldn't staff a neurophysiologist for tractography can now rely on the platform. Structural heart programs that couldn't recruit a specialist echocardiographer trained in M-TEER guidance now have a software assist. Whether those centers actually adopt quickly depends on reimbursement, training, and capital budgets. But the clearances remove the technical barrier. The commercial execution is what determines whether that access potential converts to procedure volume.
The bottom line: AI in the OR is moving from research to cleared, deployed infrastructure. The commercial strategies for Medtronic and Philips now depend on converting those clearances into procedural volume across a broader installed base than their premium platforms have historically reached. For everyone building in surgical guidance, AI-assisted procedures, or procedural workflow software, the baseline just shifted. These are the reference systems your customers are being sold this year.
Industry Shifts
Shift 01
Imaging OEMs have been consolidating their product-line architectures for years. GE HealthCare separated into a focused medtech entity. Siemens Healthineers and Philips both reorganized around unified platform stories. The pattern is coherent platform strategy over fragmented subsidiary portfolios. (Source: Imaging Technology News, March 23, 2026)
Samsung Medison's Samsung HME America rebrand puts a Korean consumer technology company's name, and associated R&D scale, directly into competition with those platform players. Samsung's semiconductor, display, and AI software capabilities are not niche.
The open question is whether Samsung Medison can translate those parent capabilities into differentiated clinical imaging hardware at a pace that competes with incumbents who have decades of radiologist workflow relationships. The rebrand announces that the attempt is serious. Execution over the next 18 months will determine whether HME America becomes a credible platform or a rebranded niche.
Strategy
Imaging
AI Platform
Shift 02
Multi-cancer early detection (MCED) is the largest greenfield diagnostic market of the decade. The market structure question, which company controls both the test and the commercial pathway to reach patients at scale, just got a provisional answer. (Source: Crain's Chicago Business, March 23, 2026)
With Exact Sciences now an Abbott subsidiary, the combined entity has Cologuard's colorectal screening franchise, Oncotype DX's oncology genomics presence, and Abbott's global distribution network across point-of-care, rapid testing, and continuous monitoring. Illumina's Grail and Guardant Health remain independent competitors in liquid biopsy.
The competitive dynamic now pits vertically integrated commercial infrastructure (Abbott) against pure-play clinical evidence strategy (Grail, Guardant). In diagnostics, commercial infrastructure typically wins at scale. The MCED market is still early enough that clinical differentiation matters, but the Abbott close changes the ground rules for the next phase of competition.
$21B Close
Oncology
Diagnostics
The Builder's Take
What the AI-in-the-OR Clearances Actually Mean If You're Building in Surgical Guidance or Procedural AI
Two things are true simultaneously about this week's clearances: they represent genuine technical progress, and they make the competitive landscape harder for independent software builders in the same space.
The Medtronic Stealth AXiS clearance means any startup selling AI-assisted surgical planning or intraoperative navigation software is now competing with a system installed in most major neurosurgery centers, freshly expanded with AI capabilities, and backed by Medtronic's enterprise sales force. That is a structurally difficult position.
The path forward for independent builders is not to build a better Stealth AXiS. It's to identify what the Stealth AXiS doesn't do: multi-modal data fusion beyond standard navigation modalities, postoperative outcome tracking linked to intraoperative navigation decisions, AI assistance in procedure types where Stealth has limited coverage, or workflow integrations with EMR systems that Medtronic hasn't prioritized.
The Philips DeviceGuide clearance creates a similar dynamic in structural heart. Procedural AI tied to a specific imaging platform and a specific device (PASCAL Ace) is commercially powerful but also narrow.
Centers using Abbott MitraClip instead of Edwards PASCAL Ace don't have a DeviceGuide equivalent yet. Centers using non-Philips imaging infrastructure don't fit the cleared workflow. Those gaps are where independent builders can operate.
The broader pattern: as platform vendors add AI capabilities to their installed base, the addressable market for independent procedural AI narrows in covered segments and expands in uncovered ones. The job for builders is to identify which uncovered segments have both clinical unmet need and a realistic path to hospital procurement.
That analysis is harder than it sounds, but it's the right starting point. What Medtronic and Philips cleared this week tells you where they focused. The rest of the map is still open.
Fun Fact & Trivia
Fun Fact
Surgical navigation using preoperative imaging dates to the early 1990s, when Vanderbilt University researchers developed frameless stereotaxy systems that register a patient's MRI to physical space in the OR using fiducial markers. The first commercial systems required surgeons to manually touch anatomical landmarks with a tracked probe, a process called patient registration.
Modern AI-based automatic registration in platforms like Medtronic's Stealth AXiS now compresses that process, using surface scanning and AI matching, from 10–15 minutes of manual work into seconds. A direct line runs from those early Vanderbilt experiments to the OR today.
MedTech Trivia
Philips' DeviceGuide AI software for mitral valve repair was developed in collaboration with Edwards Lifesciences and is designed for use with which specific Edwards structural heart device?
👇 Scroll to the footer for the answer
MedTech Word Search
🧩 Find the Hidden MedTech Terms, Click to Highlight
STEALTH
SAMSUNG
MINIMED
NEURAL
PHILIPS
MITRAL
Words hidden horizontally (→) and vertically (↓). Click letters to mark your finds.
Quick Question
Builders and clinicians, where do you see the most unmet need in intraoperative AI right now? Surgical navigation, structural heart guidance, real-time tissue identification, or something else entirely? I want to know where practitioners and founders are actually looking. Hit reply, I read every response.
Sponsor
